Chronic hepatitis C (CHC) significantly affects the prognosis
of liver disease [1] and health related quality of life (HRQOL)
in patients with β-thalassemia major [2, 3]. CHC cure is a
crucial event in the prognosis of the disease, since prevents
fibrosis progression, decreases the risk of hepatocellular carcinoma (HCC), and improves survival. Standard antiviral
therapy with Pegylated Interferon (PEG-IFN) and Ribavirin
(RBV) has long been the standard of care, despite its limited
efficacy and increased ribavirin induced hematological adverse events in thalassemic patients [4]. Recently, several novel highly effective direct antiviral agents (DAAs) have been
approved for HCV treatment, with impressive cure rates,
higher than 90%, after 8–12 weeks of therapy and mild adverse events [5], but there are no published reports
documenting the efficacy, safety and impact on QOL of available interferon-free antiviral regimens in patients with βthalassemia majo
